Thane Wettig, the CEO of $FGEN, bought 145,000 shares of the company on 03-24-2025 for an estimated $50,663. This trade was reported by Quiver Quantitative using data ...

The worries about the election and the ongoing uncertainty about the path of interest-rate increases have been keeping investors on the sidelines. Of course, most hedge funds and other asset managers ...

The pamrevlumab development program will be terminated, and the company plans to wind down any remaining pamrevlumab obligations. The company plans to implement an immediate and significant cost ...

FibroGen Inc (NASDAQ:FGEN) stock is sliding today, after the biotech company announced disappointing results from a late-stage trial of pamrevlumab, its experimental drug to treat patients with ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. It was a busy week for the biotech sector, with quite a ...